|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.03|
There is one clinical trial.
A lot of people suffer from phobias. Phobias concerning certain diseases are not rare. This study will examine whether the COVID-19 (Coronavirus Disease) crisis was able to rise phobias in people and if those with preexisting phobias or fears were more likely to develop a phobia concerning COVID. It will look at different subtypes - physicians, medical staff, general public (not medically affiliated) and patients with psychiatric disorders.
Description: Specific Phobia Questionnaire (SPQ): The SPQ consists of 43 items, each rated using a 5-point Likert scale on two dimensions: (1) level of fear, with scores ranging from 0 (no fear) to 4 (extreme fear) and (2) extent to which the fear interferes with one's daily life, with scores ranging from 0 (no interference) to 4 (extreme interference). The SPQ is scored by combining fear ratings of each DSM-5 specific phobia type. Severity Measure for Specific Phobia-Adult: The total score can range from 0 to 40 with higher scores indicating greater severity of specific phobia.Measure: Development of phobias Time: 2 years
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports